Real-world Outcomes of Durvalumab Consolidation in Elderly Patients With Unresectable NSCLC Following CCRT With Daily Low-dose Carboplatin.

IF 1.6 4区医学 Q4 ONCOLOGY Anticancer research Pub Date : 2025-01-01 DOI:10.21873/anticanres.17425

Keijiro Yamauchi, Riiko Komuta, Hidetaka Tanabe, Masashi Yokoyama, S O Takata, Takafumi Yanase, Yuki Hosono, Shingo Satoh, Naoko Morishita, Hidekazu Suzuki

{"title":"Real-world Outcomes of Durvalumab Consolidation in Elderly Patients With Unresectable NSCLC Following CCRT With Daily Low-dose Carboplatin.","authors":"Keijiro Yamauchi, Riiko Komuta, Hidetaka Tanabe, Masashi Yokoyama, S O Takata, Takafumi Yanase, Yuki Hosono, Shingo Satoh, Naoko Morishita, Hidekazu Suzuki","doi":"10.21873/anticanres.17425","DOIUrl":null,"url":null,"abstract":"Background/aim: The clinical benefits of durvalumab consolidation therapy following concurrent chemoradiotherapy (CCRT) with daily low-dose carboplatin in elderly patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) remain unclear.Patients and methods: This was a single-institution retrospective cohort study. We analyzed the medical records of consecutive patients diagnosed with NSCLC who received CCRT with daily low-dose carboplatin from April 2014 to March 2021. Outcomes were compared between the overall group and two subgroups: those who received durvalumab consolidation therapy (CCRT-durvalumab group) and those who did not (CCRT-alone group). The primary endpoints were progression-free survival (PFS) and overall survival (OS).Results: A total of 38 patients (median age: 76 years) were enrolled in this study. The median PFS was 9.9 months in the overall group, 11.7 months in the CCRT-durvalumab group, and 10.2 months in the CCRT-alone group. The median OS was 39.4 months in the overall group, 32.0 months in the CCRT-durvalumab group, and 39.4 months in the CCRT-alone group. There were no significant differences between the two subgroups in terms of PFS [hazard ratio (HR)=0.88, p=0.97] or OS (HR=1.21, p=0.70).Conclusion: In real-world settings, durvalumab consolidation therapy following CCRT with daily low-dose carboplatin does not appear to provide clinical benefits in terms of PFS or OS for elderly patients with unresectable, locally advanced NSCLC.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 1","pages":"369-378"},"PeriodicalIF":1.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17425","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: The clinical benefits of durvalumab consolidation therapy following concurrent chemoradiotherapy (CCRT) with daily low-dose carboplatin in elderly patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) remain unclear.

Patients and methods: This was a single-institution retrospective cohort study. We analyzed the medical records of consecutive patients diagnosed with NSCLC who received CCRT with daily low-dose carboplatin from April 2014 to March 2021. Outcomes were compared between the overall group and two subgroups: those who received durvalumab consolidation therapy (CCRT-durvalumab group) and those who did not (CCRT-alone group). The primary endpoints were progression-free survival (PFS) and overall survival (OS).

Results: A total of 38 patients (median age: 76 years) were enrolled in this study. The median PFS was 9.9 months in the overall group, 11.7 months in the CCRT-durvalumab group, and 10.2 months in the CCRT-alone group. The median OS was 39.4 months in the overall group, 32.0 months in the CCRT-durvalumab group, and 39.4 months in the CCRT-alone group. There were no significant differences between the two subgroups in terms of PFS [hazard ratio (HR)=0.88, p=0.97] or OS (HR=1.21, p=0.70).

Conclusion: In real-world settings, durvalumab consolidation therapy following CCRT with daily low-dose carboplatin does not appear to provide clinical benefits in terms of PFS or OS for elderly patients with unresectable, locally advanced NSCLC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

每日低剂量卡铂治疗老年不可切除非小细胞肺癌患者CCRT后Durvalumab巩固的实际结果

背景/目的：对于不能切除的局部晚期非小细胞肺癌（NSCLC）老年患者，每日低剂量卡铂同步放化疗（CCRT）后durvalumab巩固治疗的临床获益尚不清楚。患者和方法：这是一项单机构回顾性队列研究。我们分析了2014年4月至2021年3月连续接受CCRT并每日低剂量卡铂治疗的非小细胞肺癌患者的病历。结果比较了整个组和两个亚组：接受durvalumab巩固治疗的组（CCRT-durvalumab组）和未接受durvalumab巩固治疗的组（ccrt单独组）。主要终点为无进展生存期（PFS）和总生存期（OS）。结果：共有38例患者（中位年龄：76岁）入组本研究。整体组的中位PFS为9.9个月，CCRT-durvalumab组为11.7个月，单独ccrt组为10.2个月。整体组的中位OS为39.4个月，CCRT-durvalumab组为32.0个月，ccrt单独组为39.4个月。两个亚组在PFS[风险比(HR)=0.88, p=0.97]或OS （HR=1.21, p=0.70）方面无显著差异。结论：在现实环境中，对于无法切除的局部晚期非小细胞肺癌老年患者，CCRT后每日低剂量卡铂的durvalumab巩固治疗似乎并没有提供PFS或OS方面的临床益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.